Assessment of the steady-state drug–drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescents
Administration of DRV/r 800/100 mg and DTG 50 mg once daily provides adequate concentrations and exposures with no clinically relevant drug-drug interactions at steady-state.
Authors
- Tim Roy Cressey (ORCID: https://orcid.org/0000-0002-8106-0974)
- Alasdair Bamford (ORCID: https://orcid.org/0000-0003-4764-229X)
- Seef Abdalla (ORCID: https://orcid.org/0000-0001-6195-1502)
- Déborah Hirt (ORCID: https://orcid.org/0000-0002-9898-2609)
- Carlo Giaquinto (ORCID: https://orcid.org/0000-0001-9365-0413)
- Alexandra Compagnucci
- Thao‐Nguyen Nguyen
- Jean‐Marc Tréluyer (ORCID: https://orcid.org/0000-0002-2045-4742)
- Yoann Riault
- Man K. Chan (ORCID: https://orcid.org/0000-0002-4866-5170)
- José Tomás Ramos (ORCID: https://orcid.org/0000-0002-3874-4481)
- Valentin Constant
- Yacine Saïdi
Institutions
- Universidad Complutense de Madrid (ES)
- Hôpital Necker-Enfants Malades (FR)
- University of Liverpool (GB)
- Inserm (FR)
- Université Paris Cité (FR)
- Great Ormond Street Hospital for Children NHS Foundation Trust (GB)
- Hospital Clínico San Carlos (ES)
- PENTA Foundation (IT)
- MRC Clinical Trials Unit at UCL (GB)
- Sorbonne Paris Cité (FR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Centro de Investigación Biomédica en Red (ES)
- Chiang Mai University (TH)
Publication Details
- Journal
- AIDS
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1097/qad.0000000000004223
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00